Melanoma Clinical Trials in San Francisco

Showing 61-80 of 82 trials

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

NCT01227551

The purpose of this study is to assess the clinical efficacy of Intratumoral (IT) CVA21 in terms of immune-related Progression-Free Survival (irPFS) at 6 months as monitored via immune-related Response Criteria \[irRECIST 1.1\] (revised Response Evaluation Criteria In Solid Tumors \[RECIST\] 1.1).

Malignant Melanoma

Viralytics57 participantsStarted Dec 2011

La Jolla, California, United States • San Francisco, California, United States • Miami Beach, Florida, United States +7 more locations

COMPLETEDPHASE1< 1 mile

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

NCT02027961

The purpose of this study is to determine the maximum tolerated dose and characterize the safety profile of durvalumab (MEDI4736) in combination with dabrafenib and trametinib or with trametinib alone in participants with metastatic or unresectable melanoma with BRAF-mutation positive or wild-type (WT) BRAF, respectively.

Melanoma

MedImmune LLC68 participantsStarted Dec 2013

Scottsdale, Arizona, United States • Los Angeles, California, United States • San Francisco, California, United States +8 more locations

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Melanoma Trials in Other Cities

A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

S9804: Vinorelbine in Treating Patients With Stage IV Melanoma

Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

B-Receptor Signaling in Cardiomyopathy

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Phase II, 2nd Line Melanoma - RAND Monotherapy

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

Study of CP-675,206 in Refractory Melanoma

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Other Conditions in San Francisco